Skip to main navigation

Vivek Ramaswamy

Founder & CEO

Roivant Sciences

About Us
Pipeline
Our Companies
For Investors +
Join Us

Press Releases

Year

November 28, 2023

Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

November 27, 2023

Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus

November 13, 2023

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update

November 10, 2023

Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

October 30, 2023

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023

October 23, 2023

Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant

September 26, 2023

Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

September 11, 2023

Roivant Announces Completion of Redemption of its Outstanding Warrants

August 17, 2023

Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants

August 14, 2023

Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 28

Print Page
Email Alerts
RSS Feeds
IR Contacts

© 2023 Roivant Sciences Ltd.

Careers Privacy Policy

Follow us on LinkedIn